During Monday’s Current trade, Shares of Sigma-Aldrich Corporation (NASDAQ:SIAL), gain 0.07% to $139.65.
Sigma-Aldrich Corporation (SIAL), a leading Life Science and Technology Company, declared recently it has signed an exclusive global distribution agreement with IROA Technologies, LLC to distribute IROA’s Mass Spectrometry Metabolite Library of Standards™ (MSMLS). The agreement partners IROA’s MSMLS product portfolio and software with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich.
MSMLS is a collection of high-quality small molecules that span a broad range of primary metabolism. These are high purity (>95%) compounds supplied in an economical, ready-to-use format. The library of standards is most commonly used to provide retention times and spectra for key metabolic compounds, assist optimize mass spectrometry analytical protocols and qualify and quantify mass spectrometry sensitivity and limit of detection.
Under the agreement, Sigma-Aldrich has worldwide rights to sell IROA Technologies’ Mass Spectrometry Metabolite Library of Standards. Sigma-Aldrich will employ its sales, marketing and eCommerce expertise and leverage the strength of its relationships with the scientific community to present and distribute MSMLS and the corresponding software, MSMLSDiscovery™.
Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide.
Shares of AmerisourceBergen Corp. (NYSE:ABC), inclined 0.59% to $106.73, during its current trading session.
AmerisourceBergen Corporation (ABC) declared that its Board of Directors has elected D. Mark Durcan, 54, to its Board of Directors, effective right away. Mr. Durcan fills the vacancy created by Edward E. Hagenlocker’s retirement at the annual meeting of stockholders on March 5, 2015.
Mr. Durcan is presently the Chief Executive Officer and a director of Micron Technology, Inc., a global leader in advanced semiconductor systems. Mr. Durcan, a 30-year veteran of Micron, has served as Chief Executive Officer and a director since February 2012. He served as President from June 2007 until February 2012, during which time he continued in his role as Chief Operating Officer, a position he assumed in February 2006. He served as Chief Technology Officer from June 1997 to February 2006. Before his appointment as Chief Technology Officer, he held various other positions with Micron and its auxiliaries.
During Mr. Durcan’s tenure as Chief Executive Officer, Micron has become one of the largest chip makers in the world. Under his leadership, Micron has driven its next-generation technologies to market and expanded its global presence and capabilities, developing and maintaining long-standing partnerships with industry leaders, such as Intel, and concluding planned acquisitions all over the world.
AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally.
Theravance Inc (NASDAQ:THRX), during its Monday’s current trading session showed no change to $9.68.
GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) declared initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’). The study involved 16,485 patients from 43 countries who had chronic obstructive pulmonary disease (COPD) with moderate airflow limitation (FEV1 50-70% predicted) and either a history or raised risk of cardiovascular disease (CVD).
For the primary endpoint of the study, the risk of dying on FF/VI 100/25mcg was 12.2% lower than on placebo* over the study period, which was not statistically noteworthy(p=0.137).
For the first of two secondary endpoints, FF/VI 100/25mcg reduced the rate of lung function decline (as measured by forced expiratory volume in one second, ‘FEV1’) by 8mL per year contrast with placebo (p=0.019). As the primary endpoint was not met, statistical significance cannot be inferred from this result. For the other secondary endpoint, the risk of experiencing an on-treatment cardiovascular (CV) event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack [TIA]) at any time was 7.4% lower in patients taking FF/VI 100/25mcg as compared to placebo which was not statistically noteworthy(p=0.475).
Theravance, Inc., a royalty administration company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist partnership agreement and the planned alliance agreement with Glaxo Group Limited (GSK).
Finally, ReneSola Ltd. (ADR) (NYSE:SOL), gained 11.58%, to $1.06.
ReneSola Ltd (SOL), a leading brand and technology provider of energy-efficient products, recently declared that it has sold its 300 KW low voltage project in Kyoto, Japan to a local firm that intends to utilize the project to capitalize on tax incentives for investments made in small-scale renewable energy projects.
The Kyoto project is our first project sale in Japan and continues our momentum as we expand our business across key developed markets within the downstream segment of the solar industry,” said Mr. Xianshou Li, ReneSola’s chief executive officer. “The project sale is representative of our long-term strategy to build a portfolio of small-sized ground or commercial rooftop projects that we can sell to retail and institutional investors with attractive pricing and favorable payment terms. We have more than 32 MW in our Japan project pipeline and are implementing similar strategies that are focusing on small ground and commercial rooftop projects in other developed markets counting the UK, France and the US.”
The project features ReneSola Virtus modules and is qualified for Japan’s 36 Yen FIT scheme. ReneSola has closed the sale and received all proceeds from the project.
ReneSola Ltd, through its auxiliaries, manufactures and sells various solar power products. It operates through two segments, Wafer, and Cell and Module. The company offers virgin polysilicon; mono crystalline and multi crystalline solar wafers; and photovoltaic cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
